Get the Stockscreener App
1.0096
1.02%
-0.0104
After Hours:
1.01
0.0004
+0.04%
Estrella Immunopharma Inc stock is traded at $1.0096, with a volume of 12,310.
It is down -1.02% in the last 24 hours and down -7.80% over the past month.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
See More
Previous Close:
$1.02
Open:
$0.9801
24h Volume:
12,310
Relative Volume:
0.21
Market Cap:
$36.52M
Revenue:
-
Net Income/Loss:
$-8.53M
P/E Ratio:
-4.1479
EPS:
-0.2434
Net Cash Flow:
$-12.75M
1W Performance:
-2.92%
1M Performance:
-7.80%
6M Performance:
-11.05%
1Y Performance:
+14.73%
1-Day Range:
$0.97
$1.0197
1-Week Range:
$0.94
$1.05
52-Week Range:
$0.63
$3.23
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Name
Estrella Immunopharma Inc
Sector
Industry
Phone
(510) 318-9098
Address
5858 HORTON STREET, SUITE 370, EMERYVILLE
Compare ESLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
1.0096 | 37.61M | 0 | -8.53M | -12.75M | -0.2434 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Estrella Immunopharma Inc Stock (ESLA) Latest News
Estrella Immunopharma’s (ESLA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial - Yahoo
ESLA Stock Rating and Price Target Maintained by D. Boral Capita - GuruFocus
Estrella Immunopharma, Inc. Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com
Estrella Immunopharma Advances STARLIGHT-1 Clinical Trial - TipRanks
ESLA Stock Rating and Price Target Maintained by D. Boral Capital | ESLA Stock News - GuruFocus
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com
Estrella Immunopharma (ESLA) Advances in Phase I/II STARLIGHT-1 Trial | ESLA Stock News - GuruFocus
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas - Yahoo Finance
Geode Capital Management LLC Acquires 16,862 Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) - Defense World
ESLA Stock: A Voyage Through Estrella Immunopharma Inc’s Finances - investchronicle.com
A stock that deserves closer examination: Estrella Immunopharma Inc (ESLA) - uspostnews.com
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners - BioSpace
Estrella Immunopharma completes first dose cohort in STARLIGHT trial - Yahoo Finance
Sector Update: Health Care -February 21, 2025 at 03:42 pm EST - Marketscreener.com
Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study - Marketscreener.com
Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose Cohort - Marketscreener.com
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort - The Bakersfield Californian
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital - 01net
Estrella Immunopharma (NASDAQ:ESLA) Now Covered by Analysts at D. Boral Capital - Defense World
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Estrella Immunopharma regains Nasdaq compliance - Investing.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Quotes, Forecast and News Summary - Benzinga
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Estrella Immunopharma extends stock sale agreement with White Lion By Investing.com - Investing.com Canada
Estrella Immunopharma faces Nasdaq delisting over equity shortfall - Investing.com
Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider - Simply Wall St
Eureka Therapeutics Tackling Advanced Hepatocellular Carcinoma With T-Cell Therapy ECT204 in Phase 1/2 ARYA-3 Clinical Trial - CGTLive™
Estrella Immunopharma Appoints Dr. Cheng Liu as CEO - TipRanks
Tesla stock hits 52-week low at $0.75 amid market challenges - Investing.com
Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™
First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas - CGTLive®
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells - BioSpace
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member - Business Wire
Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas Doses First Patient - CGTLive®
Wall Street today: US stocks trade higher after promising inflation data raises Fed rate cut bets; 3M Co. gains 18.99% - Mint
OS Therapies (AMEX:OSTX) Stock Quotes, Forecast and News Summary - Benzinga
Estrella Immunopharma streamlines operations with subsidiary merger - Investing.com India
Laura Franco - Mintz
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances - InvestorPlace
Excision Seeks to Suppress HIV Viral Replication With EBT-101 CRISPR Gene Therapy - CGTLive™
Direct Biologics’ Phase 1 Clinical Trial Seeks to Treat Crohn Disease With Extracellular Vesicles - CGTLive™
Tenaya's Phase 1b MyPeak-1 Trial is Testing the Waters in Gene Therapy for Hypertrophic Cardiomyopathy - CGTLive™
ESLAEstrella Immunopharma Latest Stock News & Market Updates - StockTitan
ESLA Stock Price and Chart — NASDAQ:ESLA - TradingView
Estrella Immunopharma nears completion of SPAC listing - Bamboo Works
Calidi Biotherapeutics (AMEX:CLDI) Stock Quotes, Forecast and News Summary - Benzinga
Estrella and TradeUP merge to become publicly traded company - Labiotech.eu
Manufacturing Stocks Investing - MarketBeat
PepGen (NASDAQ:PEPG) Stock Quotes, Forecast and News Summary - Benzinga
TradeUP Acquisition (UPTD) Stock Price, News & Analysis - MarketBeat
Estrella Immunopharma Inc Stock (ESLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):